ERBB2 and breast cancer: In breast cancer, constitutive activity of NF-κB causes loss of estrogen receptor (ER) and resistance to chemo-, radiation-, and antibody-based therapies through signaling events downstream of ERBB2 or EGFR [9], [19], [25].